ATXS
Astria Therapeutics, Inc.
Biotechnology
Market Cap$718M
5Y Perf.-2.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ATXS vs BCAB
Revenue, margins, valuation, and 5-year total return — side by side.
BCAB
BioAtla, Inc.
Biotechnology
Market Cap$5M
5Y Perf.-98.3%
ATXS vs BCAB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ATXS | BCAB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $718M | $5M |
| Revenue (TTM) | $706K | $2M |
| Net Income (TTM) | $-124M | $-60M |
| Gross Margin | 100.0% | 100.0% |
| Operating Margin | -193.4% | -29.7% |
| Total Debt | $5M | $6M |
| Cash & Equiv. | $60M | $7M |
ATXS vs BCAB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ATXS
BCAB
| Stock | Dec 20 | Jan 26 | Return |
|---|---|---|---|
| Astria Therapeutics… (ATXS) | 100 | 98.0 | -2.0% |
| BioAtla, Inc. (BCAB) | 100 | 1.7 | -98.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ATXS vs BCAB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATXS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. BioAtla, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ATXS
Astria Therapeutics, Inc.
The Growth Play
ATXS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 30.6%
- -95.5% 10Y total return vs BCAB's -99.7%
- -21.7% revenue growth vs BCAB's -81.8%
Best for: growth exposure and long-term compounding
BCAB
BioAtla, Inc.
The Income Pick
BCAB is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.51
- Lower volatility, beta 0.51, current ratio 0.37x
- Beta 0.51, current ratio 0.37x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATXS | -21.7% revenue growth vs BCAB's -81.8% |
| Quality / Margins | BCAB | -29.8% margin vs ATXS's -175.7% |
| Stability / Safety | BCAB | Beta 0.51 vs ATXS's 1.32 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATXS | +184.6% vs BCAB's -80.6% |
| Efficiency (ROA) | ATXS | -45.6% ROA vs BCAB's -250.6% |
ATXS vs BCAB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLATXSLAGGINGBCAB
BCABBioAtla, Inc.
1leads
ATXSAstria Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs BCABMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BCAB4/4
Valuation MetricsMultiples, price ratios, and targets
ATXS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ATXS4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ATXS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BCAB leads this category, winning 4 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
BCAB is the larger business by revenue, generating $2M annually — 2.8x ATXS's $706,000. BCAB is the more profitable business, keeping -29.8% of every revenue dollar as net income compared to ATXS's -175.7%.
| Metric | ATXSAstria Therapeuti… | BCABBioAtla, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $706,000 | $2M |
| EBITDAEarnings before interest/tax | -$134M | -$59M |
| Net IncomeAfter-tax profit | -$124M | -$60M |
| Free Cash FlowCash after capex | -$120M | -$34M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -193.4% | -29.7% |
| Net MarginNet income ÷ Revenue | -175.7% | -29.8% |
| FCF MarginFCF ÷ Revenue | -170.4% | -17.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -27.9% | +46.7% |
BCAB leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
ATXS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ATXSAstria Therapeuti… | BCABBioAtla, Inc. |
|---|---|---|
| Market CapShares × price | $718M | $5M |
| Enterprise ValueMkt cap + debt − cash | $664M | $4M |
| Trailing P/EPrice ÷ TTM EPS | -7.49x | -0.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.56x |
| Price / BookPrice ÷ Book value/share | 2.21x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
ATXS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ATXS leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BCAB scores 2/9 vs ATXS's 1/9, reflecting mixed financial health.
| Metric | ATXSAstria Therapeuti… | BCABBioAtla, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -53.2% | — |
| ROA (TTM)Return on assets | -45.6% | -2.5% |
| ROICReturn on invested capital | -50.3% | — |
| ROCEReturn on capital employed | -39.4% | -4.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$54M | -$918,000 |
| Cash & Equiv.Liquid assets | $60M | $7M |
| Total DebtShort + long-term debt | $5M | $6M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ATXS leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ATXS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATXS five years ago would be worth $10,697 today (with dividends reinvested), compared to $19 for BCAB. Over the past 12 months, ATXS leads with a +184.6% total return vs BCAB's -80.6%. The 3-year compound annual growth rate (CAGR) favors ATXS at -0.1% vs BCAB's -70.1% — a key indicator of consistent wealth creation.
| Metric | ATXSAstria Therapeuti… | BCABBioAtla, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -2.4% | -83.7% |
| 1-Year ReturnPast 12 months | +184.6% | -80.6% |
| 3-Year ReturnCumulative with dividends | -0.4% | -97.3% |
| 5-Year ReturnCumulative with dividends | +7.0% | -99.8% |
| 10-Year ReturnCumulative with dividends | -95.5% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -0.1% | -70.1% |
ATXS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ATXS and BCAB each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCAB is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than ATXS's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATXS currently trades 94.7% from its 52-week high vs BCAB's 6.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ATXSAstria Therapeuti… | BCABBioAtla, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 0.51x |
| 52-Week HighHighest price in past year | $13.29 | $71.50 |
| 52-Week LowLowest price in past year | $3.69 | $0.33 |
| % of 52W HighCurrent price vs 52-week peak | +94.7% | +6.1% |
| RSI (14)Momentum oscillator 0–100 | 46.1 | 40.5 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 40K |
Evenly matched — ATXS and BCAB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ATXS as "Hold" and BCAB as "Buy". Consensus price targets imply 5647.1% upside for BCAB (target: $250) vs 54.2% for ATXS (target: $19).
| Metric | ATXSAstria Therapeuti… | BCABBioAtla, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $19.40 | $250.00 |
| # AnalystsCovering analysts | 8 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATXS leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). BCAB leads in 1 (Income & Cash Flow). 1 tied.
Best OverallAstria Therapeutics, Inc. (ATXS)Leads 3 of 6 categories
Loading custom metrics...
ATXS vs BCAB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ATXS or BCAB a better buy right now?
Analysts rate BioAtla, Inc.
(BCAB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ATXS or BCAB?
Over the past 5 years, Astria Therapeutics, Inc.
(ATXS) delivered a total return of +7. 0%, compared to -99. 8% for BioAtla, Inc. (BCAB). Over 10 years, the gap is even starker: ATXS returned -95. 5% versus BCAB's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ATXS or BCAB?
By beta (market sensitivity over 5 years), BioAtla, Inc.
(BCAB) is the lower-risk stock at 0. 51β versus Astria Therapeutics, Inc. 's 1. 32β — meaning ATXS is approximately 160% more volatile than BCAB relative to the S&P 500.
04Which is growing faster — ATXS or BCAB?
On earnings-per-share growth, the picture is similar: Astria Therapeutics, Inc.
grew EPS 30. 6% year-over-year, compared to 29. 9% for BioAtla, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ATXS or BCAB?
BioAtla, Inc.
(BCAB) is the more profitable company, earning -29. 8% net margin versus -175. 7% for Astria Therapeutics, Inc. — meaning it keeps -29. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCAB leads at -29. 7% versus -193. 4% for ATXS. At the gross margin level — before operating expenses — ATXS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ATXS or BCAB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ATXS or BCAB better for a retirement portfolio?
For long-horizon retirement investors, BioAtla, Inc.
(BCAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51)). Both have compounded well over 10 years (BCAB: -99. 7%, ATXS: -95. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ATXS and BCAB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.